ExpreS2ion’s joint venture AdaptVac granted US patent for its core platform technology
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture company AdaptVac ApS (“AdaptVac”) has been granted a US patent covering its core technology platform. This confirms the overall patentability and proprietary protection of AdaptVac’s entire pipeline and future projects. In particular, this consolidates the position of the AV001 breast cancer vaccine for which a specific divisional U.S. patent was issued in 2018.AdaptVac’s novel capsid virus-like particle (VLP) technology platform shows strong potential as a platform for the development of novel breakthrough